000061593 001__ 61593 000061593 005__ 20240122154813.0 000061593 0247_ $$2doi$$a10.1177/2050640616663689 000061593 0248_ $$2sideral$$a99463 000061593 037__ $$aART-2016-99463 000061593 041__ $$aeng 000061593 100__ $$0(orcid)0000-0001-5573-6144$$aLayunta, E.$$uUniversidad de Zaragoza 000061593 245__ $$aToll-like receptor 9 modifies intestinal serotonergic system. 000061593 260__ $$c2016 000061593 5060_ $$aAccess copy available to the general public$$fUnrestricted 000061593 5203_ $$aIntroduction: Toll-like receptor 9 (TLR9) is expressed in intestinal epithelial cells, which recognize microbiota developing different responses 1. Several studies have shown that TLR9 seems to be involved in Inflammatory Bowel Diseases (IBD) due to an inappropriate defensive response against microorganisms 2. Moreover, intestinal serotonergic system is also altered in IBD, where extracellular serotonin (5–HT) levels are increased 3. 5-HT bioavailability is mainly regulated by the serotonin transporter (SERT), expressed in enterocytes 4. Aims & Methods: The aim of the present study was to analyse whether TLR9 activation affects SERT expression and activity, and expression of other elements from the serotonergic system (TPH1, TPH2 and 5-HT receptors). Human enterocyte-like Caco-2 cells, and ileum and colon from TLR9-/- mice and Dextran Sulphate Sodium (DSS) mouse colitis model were used as experimental models. mRNA expression was determined by RT-qPCR, and protein expression by western blot... 000061593 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/ 000061593 590__ $$a3.673$$b2016 000061593 591__ $$aGASTROENTEROLOGY & HEPATOLOGY$$b21 / 79 = 0.266$$c2016$$dQ2$$eT1 000061593 592__ $$a1.137$$b2016 000061593 593__ $$aOncology$$c2016$$dQ2 000061593 593__ $$aGastroenterology$$c2016$$dQ2 000061593 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000061593 700__ $$aLatorre, E. 000061593 700__ $$aForcén, R. 000061593 700__ $$0(orcid)0000-0002-5306-9365$$aGrasa, L.$$uUniversidad de Zaragoza 000061593 700__ $$0(orcid)0000-0003-0154-0730$$aPardo, J.$$uUniversidad de Zaragoza 000061593 700__ $$aCastro, M. 000061593 700__ $$0(orcid)0000-0002-7412-2073$$aPlaza, M.A.$$uUniversidad de Zaragoza 000061593 700__ $$0(orcid)0000-0002-2114-0577$$aArruebo, M.P.$$uUniversidad de Zaragoza 000061593 700__ $$0(orcid)0000-0003-4758-3998$$aMesonero, J.E.$$uUniversidad de Zaragoza 000061593 7102_ $$11005$$2410$$aUniversidad de Zaragoza$$bDpto. Farmacología y Fisiolog.$$cÁrea Fisiología 000061593 7102_ $$11008$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Inmunología 000061593 773__ $$g4, Suppl. 1 (2016), A426-A426$$pUnited European Gastroenterol. j.$$tUnited European Gastroenterology Journal$$x2050-6406 000061593 8564_ $$s96221$$uhttps://zaguan.unizar.es/record/61593/files/texto_completo.pdf$$yVersión publicada 000061593 8564_ $$s123061$$uhttps://zaguan.unizar.es/record/61593/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000061593 909CO $$ooai:zaguan.unizar.es:61593$$particulos$$pdriver 000061593 951__ $$a2024-01-22-15:31:06 000061593 980__ $$aARTICLE